ClinicalTrials.Veeva

Menu

Understanding Chronic Lymphocytic Leukemia

Dana-Farber Cancer Institute logo

Dana-Farber Cancer Institute

Status

Enrolling

Conditions

Chronic Lymphocytic Leukemia

Study type

Observational

Funder types

Other
NIH

Identifiers

NCT04028531
R01CA213442-01A1 (U.S. NIH Grant/Contract)
99-224

Details and patient eligibility

About

The purpose of this study is to collect human Chronic Lymphocytic Leukemia tissue samples and medical information, in order to find out more about the causes and biology of chronic lymphocytic leukemia.

Full description

The purpose of this study is to collect human Chronic Lymphocytic Leukemia tissue samples and medical information, in order to find out more about the causes and biology of chronic lymphocytic leukemia, for the potential development of more effective therapies for this disease.

Enrollment

2,750 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • New and existing patients seen for treatment of monoclonal B-cell lymphocytosis
  • Any low grade lymphoproliferative disorder
  • Chronic Lymphocytic Leukemia in the Dana Farber Cancer Institute Hematologic Oncology Clinic or elsewhere

Exclusion criteria

Trial design

2,750 participants in 1 patient group

Sample Collection
Description:
* Blood tests required for assessment * Specimens and data will also be collected from outside sites * Clinical data from patients with Chronic Lymphocytic Leukemia will be gathered into a database at Dana Farber Cancer Institute

Trial contacts and locations

1

Loading...

Central trial contact

Jennifer Brown, MD, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems